结合饱和基因组编辑与乳腺癌临床表型重新分类 BRCA2 意义不明变异
Reclassification of BRCA2 Variants of Uncertain Significance Using Saturation Genome Editing Combined with Clinical Phenotypes in Breast Cancer
BRCA2 基因中许多变异意义不明（VUS，即尚不能判断是否致病），给临床决策带来困难。研究纳入 15,092 名乳腺癌患者，在 1051 名携带者中识别出 457 个不同的 BRCA2 意义不明变异，并对第 15-26 外显子内的 88 个变异用已发表的饱和基因组编辑（逐一测试大量 DNA 变异功能的方法）数据进行功能评估并分类。结果 15 个被重新归为功能致病，66 个为功能良性，7 个仍不明确。功能致病携带者的任何癌症家族史比例显著更高（65.0% 对 31.1%），功能良性者临床特征与无携带者相似。研究提示该方法结合临床表型可提高致病性判断准确性。
为什么推荐给您：将饱和基因组编辑功能数据与大队列临床表型结合重新分类变异，提升 BRCA2 判读准确性，属重要方法学进展。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
PURPOSE: To evaluate the pathogenicity of BRCA2 variants of uncertain significance (VUS) located within the functionally critical exons 15-26 using published SGE data, and to reclassify these VUS by integrating clinical phenotypes.
METHODS: A total of 15,092 breast cancer patients were enrolled in this study, among which 457 distinct BRCA2 VUS were identified in 1051 carriers. Based on SGE scores, 88 BRCA2 VUSs within exons 15-26 were functionally assessed and carriers reclassified as functionally pathogenic, functionally benign, or remaining VUS. Clinicopathological characteristics were subsequently compared across variant groups.
RESULTS: Of these 88 evaluated BRCA2 VUSs (187 carriers), 15 were reclassified as functionally pathogenic (20 carriers), 66 as functionally benign (154 carriers), and 7 remained VUS (13 carriers). Compared with non-carriers, carriers with functionally pathogenic variants exhibited a significantly higher prevalence of a family history of any cancer (65.0% vs. 31.1%, p = 0.002), particularly breast and/or ovarian cancer (35.0% vs. 10.0%, p = 0.002), as well as a trend toward a higher incidence of bilateral breast cancer (10.0% vs. 2.4%, p = 0.085). In contrast, individuals harboring functionally benign variants demonstrated clinicopathological characteristics similar to non-carriers.
CONCLUSION: SGE-based functional scoring system provides a reliable approach for reclassifying BRCA2 VUS. When integrated with clinical phenotypes, it enhanced the accuracy of pathogenicity assessment.